Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria - 19/04/17
Doi : 10.1016/j.jaci.2016.07.047
Janine Gericke, PhD a, ∗, Martin Metz, MD a, ∗, Tatevik Ohanyan, MD a, Karsten Weller, MD a, Sabine Altrichter, MD a, Per Stahl Skov, MD b, c, d, Sidsel Falkencrone, PhD c, Janko Brand, PhD e, Arno Kromminga, PhD f, Tomasz Hawro, MD a, Martin K. Church, PhD, DSc a, Marcus Maurer, MD a 
a Department of Dermatology, Venerology and Allergy, Allergie-Centrum Charité, Charité - Universitätsmedizin, Berlin, Germany
b Dermatological Department, University Hospital of Southern Denmark, Odense, Denmark
c RefLab ApS, Copenhagen, Denmark
d Institute of Immunology, National University of Copenhagen, Copenhagen, Denmark
e BioTeZ Berlin-Buch GmbH, Berlin, Germany
f IPM Biotech GmbH, Hamburg, Germany
| Disclosure of potential conflict of interest: J. Gericke's institution has received grants from Novartis Pharma GmbH. M. Metz has received consultancy fees from Medixiline, Index Venture Management Jersey Ltd, Sanofi, Nerre, LORA Group, Jenapharm, and Novartis; payment for lectures from Novartis, Charité, Bayer, MarDi, Dr. R. Pfleger, Urtimed, Klinikzentrum Bad Sulza, GlaxoKline, DDG, ADF, Jenapharm, Universität Münster, Roche, Ärztekammer Berlin, and BVDD; and payment for manuscript preparation from Mediengruppe Oberfranken, Jenapharm, and Moxie GmbH. K. Weller has received consultancy fees, grants, and payment for lectures from Novartis. S. Altrichter is employed by Charite-Universitätsmedizin Berlin and has received grants from Rahel-Hirsch-Stipend. P. S. Skov has received consultancy fees from RefLab ApS. S. Falkencrone is employed by RefLab ApS. A. Kromminga is employed by and has received stock options from IPM Biotech GmbH. M. K. Church has received grants or honorarium and support for travel from Novartis for the work under consideration for publication. M. Maurer has received board membership, consultancy fees, expert testimony fees, and grants from Uriach, Novartis, Genentech, and Moxie and payment for lectures from Uriach and Novartis. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 3
P. 1059 - mars 2017 Retour au numéro
Article précédent
- Adult atopic dermatitis and the risk of type 2 diabetes
- Yuki M.F. Andersen, Alexander Egeberg, Gunnar H. Gislason, Lone Skov, Filip K. Knop, Jacob P. Thyssen
- Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes
- Matthew A. Tyler, Chris B. Russell, Dirk E. Smith, James B. Rottman, Caroline J. Padro Dietz, Xuguang Hu, Martin J. Citardi, Samer Fakhri, Shervin Assassi, Amber Luong
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?